Log in

MGC Pharmaceuticals Stock Price, News & Analysis (ASX:MXC)

0.00 (0.00 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
Now: A$0.04
50-Day Range
MA: A$0.04
52-Week Range
Now: A$0.04
Volume1.16 million shs
Average VolumeN/A
Market Capitalization$43.68 million
P/E RatioN/A
Dividend YieldN/A
MGC Pharmaceuticals Limited, a biopharmaceutical company, produces and supplies medicinal cannabis products in Australia, Slovenia, and other European countries. It is developing phytocannabinoid as active pharmaceutical ingredients (API) for medicinal cannabis products. The company offers MGC MX201 for relief from nausea, vomiting, pain related to chemotherapy treatment, and Tourette syndrome disorder; and MGC MX21 for acquired immunodeficiency syndrome (AIDS), weight loss CAC, and the enhancement of appetite or relief from gastrointestinal vomiting and symptoms, and Parkinson's disease. It also offers MGC MX11 for neuropathy, multiple sclerosis, and Tourette syndrome; and MGC MX120 for epilepsy, inflammatory bowel disease, Crohn's disease, ulcerative colitis, and post-traumatic stress disorder. In addition, the company provides pharmaceutical products, such as Tetrinol for the treatment of cachexia; CannEpil and CannEKids for refractory epilepsy; and TopiCann for anti-inflammatory topical treatment. Further, it offers MGC CBD for anti-inflammatory, antioxidant, neuroprotector, anxiolytic, analgesic, antidepressant, anti-psychotic, and anti-tumoral agent; and MGC THC for nausea and vomiting associated with cancer medicines, as well as enhance the appetite of people with AIDS. Additionally, the company offers nutraceuticals, including CBD cosmetics and hempenhanced products for retail customers online. MGC Pharmaceuticals Limited has a collaboration with Epilepsy Action Australia to create an online platform for providing information and education on medicinal cannabis and epilepsy; and partnership with the Royal Melbourne Institute of Technology and The Hebrew University of Jerusalem to form a medical research hub for medicinal cannabis technologies. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is based in West Perth, Australia.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Phone61 8 6382 3390



Sales & Book Value

Annual Sales$656,237.00
Cash FlowA$0.00 per share
Book ValueA$0.01 per share



Outstanding Shares1,213,379,968
Market Cap$43.68 million
Next Earnings DateN/A
OptionableNot Optionable

Receive MXC News and Ratings via Email

Sign-up to receive the latest news and ratings for MXC and its competitors with MarketBeat's FREE daily newsletter.

MGC Pharmaceuticals (ASX:MXC) Frequently Asked Questions

What is MGC Pharmaceuticals' stock symbol?

MGC Pharmaceuticals trades on the ASX under the ticker symbol "MXC."

Has MGC Pharmaceuticals been receiving favorable news coverage?

Media headlines about MXC stock have trended somewhat positive on Saturday, according to InfoTrie. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. MGC Pharmaceuticals earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for MGC Pharmaceuticals.

Who are some of MGC Pharmaceuticals' key competitors?

What other stocks do shareholders of MGC Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MGC Pharmaceuticals investors own include Intel (INTC), Triton Minerals (TON), Northern Minerals (NTU), Laneway Resources (LNY) and Azure Minerals (AZS).

Who are MGC Pharmaceuticals' key executives?

MGC Pharmaceuticals' management team includes the folowing people:
  • Mr. Brett Anthony Mitchell, Exec. Chairman (Age 46)
  • Mr. Roby Reuven Zomer, Co-Founder, CEO, MD & Exec. Director
  • Mr. Nativ Segev, Co-Founder, Head of Bus. Strategy & Exec. Director
  • Ms. Rachel Jelleff Kerr, Company Sec.
  • Hugh Winters, Chief Exec. Officer of MGC Derma

What is MGC Pharmaceuticals' stock price today?

One share of MXC stock can currently be purchased for approximately A$0.04.

How big of a company is MGC Pharmaceuticals?

MGC Pharmaceuticals has a market capitalization of $43.68 million and generates $656,237.00 in revenue each year. View Additional Information About MGC Pharmaceuticals.

What is MGC Pharmaceuticals' official website?

The official website for MGC Pharmaceuticals is http://www.mgcpharma.com.au/.

How can I contact MGC Pharmaceuticals?

The company can be reached via phone at 61 8 6382 3390.

MarketBeat Community Rating for MGC Pharmaceuticals (ASX MXC)

Community Ranking:  1.4 out of 5 (star)
Outperform Votes:  11 (Vote Outperform)
Underperform Votes:  29 (Vote Underperform)
Total Votes:  40
MarketBeat's community ratings are surveys of what our community members think about MGC Pharmaceuticals and other stocks. Vote "Outperform" if you believe MXC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MXC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/19/2019 by MarketBeat.com Staff

Featured Article: What is a management fee?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel